# Doximity (DOCS) Q1 FY2027 earnings

Results filed 2026-08-06 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/docs/2027-q1/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000038/0001516513-26-000038-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Doximity's clinical AI assistant Ask ranked as the top U.S.-based model on the NOHARM benchmark, while workflow active prescriber growth topped 30% year-over-year.

Doximity pushed further into AI-assisted clinical work this quarter. Its assistant Ask (formerly DoxGPT) was the top-performing U.S.-based model in the NOHARM benchmark, and AI Search queries grew over 25% quarter-over-quarter. Providers who use workflow tools such as Dialer, Scribe, Amion, PeerCheck and Ask grew more than 30% year-over-year. Management also points to early wins in innovation budgets and in pharma, where it says it offers a lower-cost option.
Management is positioning AI as the next chapter of the doctor's digital platform, a network that reaches more than 85% of U.S. physicians. The tension is competition and cost. Scribe competes against Microsoft in a crowded market, and the AI push comes with sharply higher R&D and cost of revenue. That is squeezing margins while the company tries to convert engagement into revenue.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $156.6 million | up 7% year-over-year | GAAP |
| Net income | $24.3 million | versus $53.3 million a year ago | GAAP |
| Diluted EPS | $0.13 | versus $0.27 a year ago | GAAP |
| Non-GAAP diluted EPS | $0.29 | versus $0.36 a year ago | non-GAAP |
| GAAP gross margin | 84.9% | versus 89.2% a year ago | GAAP |
| Income from operations | 33,644 | versus 54,517 a year ago | GAAP |
| Operating cash flow | $42.0 million | a decrease of 32% year-over-year |  |
| Free cash flow | $39.6 million | a decrease of 34% year-over-year | non-GAAP |
| Adjusted EBITDA | $74.8 million | a decrease of 6% year-over-year | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Workflow active prescriber growth | more than 30% | year-over-year |
| AI Search query growth | over 25% | quarter-over-quarter |
| Share of U.S. physicians in network | more than 85% |  |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue | fiscal second quarter ending September 30, 2026 | between $170 million and $171 million |
| Adjusted EBITDA | fiscal second quarter ending September 30, 2026 | between $80.5 million and $81.5 million |
| Revenue | fiscal year ending March 31, 2027 | between $671 million and $681 million |
| Adjusted EBITDA | fiscal year ending March 31, 2027 | between $309 million and $329 million |

## Key takeaways

1. **Ask tops U.S.-based models on NOHARM benchmark** Doximity says its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Independent safety-style validation supports trust with clinicians and buyers.
2. **Workflow active prescribers grew more than 30%** Workflow active prescriber growth exceeded 30% year-over-year. The metric counts providers using tools such as Dialer, fax, Ask, PeerCheck, Amion and Scribe, so it shows adoption beyond the core network.
3. **AI Search queries up over 25% sequentially** AI Search query growth was over 25% quarter-over-quarter. Rapid usage growth gives Doximity a high-intent audience for new AI products and for pharma customers.
4. **AI Search is opening innovation and pharma budgets** Management says AI Search is starting to win innovation budget, and that pharma has been a surprise source of added market opportunity. It is entering with a lower-cost offering than what customers may have used before.
5. **AI investment is weighing on margins** R&D, sales and marketing, and cost of revenue all rose faster than revenue, and stock-based compensation climbed. Net income margin fell to 15.5% from 36.5%, so the cost of building clinical AI is itself part of the story.

## Questions

**What was Doximity's main product highlight this quarter?** Its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Management paired this with record engagement.
**How is customer and clinician usage trending?** Workflow active prescriber growth was more than 30% year-over-year, and AI Search query growth was over 25% quarter-over-quarter. Doximity's network includes more than 85% of U.S. physicians.
**Where is new demand for Doximity's AI products coming from?** Management says AI Search is starting to win innovation budget at health systems, and that pharma has been an unexpected opportunity. It is pitching pharma a lower-cost offering than customers may have used before.
**Who does Doximity compete with in AI?** In the ambient scribe market, management names Microsoft as the leader. Doximity competes with Scribe, its HIPAA-compliant ambient note-taking tool, and with Ask, its clinical AI assistant.
**What is the tradeoff in Doximity's AI strategy?** Management says it can still post strong software margins while investing heavily in clinical AI. Even so, R&D and cost of revenue rose faster than revenue, and margins fell from a year ago.

## Slides and investor documents

- [Prepared Remarks](https://s201.q4cdn.com/617428576/files/doc_financials/2027/q1/Doximity-1Q27-Earnings-Call-Prepared-Remarks.pdf) (CFO commentary)
- [Earnings Webcast](https://events.q4inc.com/attendee/534288468) (Webcast replay)
- [Quarterly Filing](https://s201.q4cdn.com/617428576/files/doc_financials/2027/q1/Doximity-1Q27-Earnings-Call-10Q.pdf) (Document)

